Three imaging-guided PCI trials (two with surprising results), LDL targets, an oral PCSK9 inhibitor, and another beta-blocker withdrawal trial are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I IVUS-Guided PCI

OPTIMAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600440
IVUS-CHIP Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601521
ILUMIEN IV Trial https://www.nejm.org/doi/10.1056/NEJMoa2305861
DKCRUSH VIII Trial https://doi.org/10.1016/j.jacc.2026.01.081

II Ez-PAVE Trial — Low vs Very Low LDL-targets

Does Ez-PAVE Support 'Lower Is Better' for LDL-C? https://www.medscape.com/viewarticle/does-ez-pave-support-lower-better-ldl-c-2026a1000akx

Ez-PAVE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600283
2026 ACC/AHA Lipid Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423

III CORALreef AddOn

CORALreef AddOn Trial https://www.jacc.org/doi/abs/10.1016/j.jacc.2026.03.036
This Week in Caardiology 2-6-26 https://www.medscape.com/viewarticle/1003240
CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002

IV Another Post-MI Beta-blocker Withdrawal Study: SMART-DECISION

SMART-DECISION Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601005
ABYSS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net